Novel tumor-selective chemotherapeutic agents

A compound comprising a structure having the following formula:

• CC-1065 analogue-linker-maleimide (Formula I)
• or a pharmaceutically acceptable salt thereof, wherein:
• A. the linker is selected from the group consisting of —C(O)R1—, —C(O)OR1—,
• —C(O)NR2R3—, —C(O)(CH2)n1(OCH2CH2)n2—, where n1 is 1-6, and n2 is 0-20;
• —C(O)(CH2)n1R4(OCH2CH2)n2— where n3 and n4 are independently 0-10;
• —C(O)(CH2)n1R4(OCH2CH2)n2— where n1 is 1-6, and n2 is 0-20;
• —C(O)(CH2)n1(OCH2CH2)n2R4— where n1 is 1-6, and n2 is 0-20;
• —C(O)NR2R3(CH2)n3R4(CH2)n4— where n3 and n4 are independently 0-10;
• and
• —C(O)NR2R3(CH2)n5(OCH2CH2)n6— where n5 and n6 are independently 0-10;
• and
• wherein
• R1 is alkyl or aryl;
• R2 and R3 are independently H, alkyl or aryl;
• but R2 and R3 cannot simultaneously be aryl;
• R4 is a valence bond, aryl, or alkyl containing at least one nitrogen;
• B. the CC-1065 analogue comprises a compound with the following structure (Formula II), wherein:
• A is a 5-6 member ring alkyl, aryl or heteroaryl;
• R5 is CH2Cl, CH2Br, CH2I or CH2OSO2CH3;
• R6 is a valence bond, a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl or an aryl;
• R7 and R9 are independently selected from aryl or heteroaryl;
• and
• M is 0-2;
• and
• C. maleimide.